The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors
{{output}}
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy represent the standard of care for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC). While clinical trials established their efficacy, real-worl... ...
